Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)
29 Gennaio 2020 - 3:08PM
Edgar (US Regulatory)
Novartis AG
Novartis Campus
4002 Basel
Switzerland
Telephone : +41 61 324 1111
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
January 29, 2020
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on January 29, 2020.
Respectfully submitted,
Novartis AG
/s/ SHANNON THYME KLINGER
|
/s/ HARRY KIRSCH
|
Shannon Thyme Klinger
|
Harry Kirsch
|
General Counsel
|
Chief Financial Officer
|
Novartis Group
|
Novartis Group
|
Grafico Azioni Novartis Ag Basel Namen ... (PK) (USOTC:NVSEF)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Novartis Ag Basel Namen ... (PK) (USOTC:NVSEF)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Novartis Ag Basel Namen Akt (PK) (OTCMarkets): 0 articoli recenti
Più Novartis Ag Articoli Notizie